79440-34-9

Usage

Uses

Used in Organic Synthesis:
6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is used as a building block in organic synthesis for the preparation of a wide range of biologically active substances and pharmaceutical drugs. Its bromomethyl group allows for further functionalization and modification, enabling the creation of diverse organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is used as a key intermediate in the development of new drugs. Its unique structure and reactivity contribute to the design and synthesis of potential therapeutic agents with various pharmacological properties.
Used in Medicinal Chemistry:
6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is utilized in medicinal chemistry for the production of compounds with potential applications in the treatment and management of various diseases and conditions. Its versatility as a building block allows for the exploration of new chemical entities with improved efficacy and selectivity.
Used in Agrochemicals:
In the agrochemical industry, 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is employed as a starting material for the synthesis of bioactive compounds with pesticidal, herbicidal, or fungicidal properties. Its unique structure and reactivity enable the development of novel agrochemicals with enhanced performance and selectivity.
Used in Materials Science:
6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is also of interest in materials science for the development of new materials with specific properties. Its potential use in the synthesis of polymers, coatings, and other materials can lead to the creation of innovative products with improved performance characteristics.

Upstream product

• 39270-39-8 (2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanol 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 169045-07-2 2-{[4-chloro-3-(methyloxy)phenyl]methyl}-1H-isoindole-1,3(2H)-dione 
• 247570-06-5 N-(3,4-ethylenedioxybenzyl)phthalimide 
• 1239355-12-4 2-{[2-chloro-4-(trifluoromethyl)phenyl]oxy}-N-[(1R)-1-{[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)oxy]methyl}-2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyridine-3-carboxamide 
• 1400793-43-2 7-[3-(benzylideneamino)methyl-4-(3',4'-ethylenedixoybenzyloxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 
• 247569-42-2 (4-chloro-3-methoxyphenyl)methanamine 
• 247568-43-0 2-[1-(tert-butoxycarbonyl)-4-piperidinylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247566-98-9 2-(1-Benzylpiperidin-4-ylamino)-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247566-97-8 2-[1-(Ethoxycarbonyl)piperidin-4-ylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247568-42-9 2-(4-carboxycyclohexylamino)-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247568-41-8 2-[4-(methoxycarbonyl)cyclohexylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247567-04-0 2-[1-(Hydroxymethyl)cyclopentylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 
• 247566-99-0 2-[2-Hydroxy-1,1-bis(hydroxymethyl)ethylamino]-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 

Relevant academic research and scientific papers

INHIBITORS FOR THE Β-CATENIN / T-CELL FACTOR PROTEIN–PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents

1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-substituted-phenylpiperazine moiety was prepared and has been found to be a new and selective ligand for the enzyme cyclooxygenase-2 (COX-2). The biological activity of compound 3k as anti-inflammatory agent was further investigated both in vitro and in vivo. Notably, compound 3k exhibited the best anti-inflammatory activity among the eleven designed compounds with no toxicity, as determined by the ulcerogenic activity. Computational docking studies also showed that compound 3k has interaction with COX-2 key residues in the active site. Compound 3k maybe a new anti-inflammatory lead-candidate as powerful and novel non-ulcerogenic.

Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: 90: 1 μg/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 μg/mL). Crown Copyright

Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2

This manuscript concludes the Structure Activity Relationship (SAR) on the pyridazinone scaffold and identifies a compound with subnanomolar p38α activity and 24 h coverage in the rat arthritis efficacy model.

Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity

Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The present invention comprises glucosylceramide synthase (GCS) inhibitors of structural formula (I), and pharmaceutically acceptable salts thereof, wherein R1, E, A, L, X1, Q, R4, R5, m and n, are as defined he

FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE

The invention relates to thiazole compounds of Formula (I) and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

Synthesis of isoquinolines and tetrahydroisoquinolines as potential antitumour agents

The isoquinoline 17 and the tetrahydroisoquinoline 16 were synthesized from 2,3-dihydro-1,4-benzodioxin (1) by different synthetic strategies. Preparation of arylethylamines and their cyclization in Bischler-Napieralski conditions have been studied. Another approach to isoquinolines was based on the amination of the ketone 13 followed by cyclization in acidic media. The route via the amide 15 was found to be more successful with respect to both yield and ease of reaction.